Mizuho Securities Sticks to Its Buy Rating for Xeris Pharmaceuticals (XERS)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Xeris Pharmaceuticals (XERS) today and set a price target of $9.00. The company’s shares closed last Thursday at $3.96.

According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.2% and a 37.5% success rate. Yang covers the Healthcare sector, focusing on stocks such as Freeline Therapeutics Holdings, Sarepta Therapeutics, and Magenta Therapeutics.

Xeris Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $9.00.

See today’s analyst top recommended stocks >>

Xeris Pharmaceuticals’ market cap is currently $262.8M and has a P/E ratio of -2.40. The company has a Price to Book ratio of 6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Xeris Pharmaceuticals, Inc.is a pharmaceutical company, which develops and commercializes ready-to-use, liquid-stable injectables. It offers XeriSol™ and XeriJect™ formulation technologies. The company was founded by Steven Prestrelski and John Kinzell in 2005 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts